Regulatory milestones

Biogen Idec Inc. (NASDAQ:BIIB) gained $3.68 to $172.38 after it and partner Swedish Orphan Biovitrum AB (SSE:SOBI) announced FDA accepted for review a BLA for rFIXFc to treat hemophilia B. Biogen Idec said the application was submitted during 4Q12; a standard review would place the PDUFA date in 4Q13, a specific date is not disclosed.